Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Operating Leases (2019 - 2024)

Whitehawk Therapeutics (WHWK) has disclosed Operating Leases for 6 consecutive years, with $565000.0 as the latest value for Q4 2024.

  • Quarterly Operating Leases fell 55.41% to $565000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $565000.0 through Dec 2024, down 55.41% year-over-year, with the annual reading at $565000.0 for FY2024, 55.41% down from the prior year.
  • Operating Leases for Q4 2024 was $565000.0 at Whitehawk Therapeutics, down from $624000.0 in the prior quarter.
  • The five-year high for Operating Leases was $1.8 million in Q2 2022, with the low at $9955.0 in Q2 2020.
  • Average Operating Leases over 5 years is $917507.9, with a median of $922500.0 recorded in 2024.
  • The sharpest move saw Operating Leases crashed 96.54% in 2020, then skyrocketed 174.55% in 2022.
  • Over 5 years, Operating Leases stood at $9955.0 in 2020, then skyrocketed by 5977.35% to $605000.0 in 2021, then soared by 174.55% to $1.7 million in 2022, then decreased by 23.72% to $1.3 million in 2023, then plummeted by 55.41% to $565000.0 in 2024.
  • According to Business Quant data, Operating Leases over the past three periods came in at $565000.0, $624000.0, and $682000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.